

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Noble et al.	)	Examiner:
			)	GiGi Huang
Serial No.	:	10/529,314	)	
			)	Art Unit:
Cnfrm No.	:	8649	)	1618
			)	
Filed	:	September 25, 2003	)	
			)	
For	:	CASPASE INHIBITORS AS ANTICANCER	)	
		AGENTS	)	
			)	

---

RESPONSE TO RESTRICTION/ELECTION OF SPECIES REQUIREMENTS

**Mail Stop Amendment**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This submission is in response to the October 31, 2007, office action, which imposed restriction and election of species requirements in the above-identified application.

In response to the restriction requirement, applicants hereby elect Group II (i.e., claims 13-23) with traverse to the extent that claims 13-15 of Group II recite use of a composition according to Group I.

In response to the election of species requirement, applicants hereby elect as the species: (i) caspase 3 inhibitor, and (ii) an alkylating anti-cancer agent. Claims of Group II reading on the elected species include claims 13-18 and 20-23.

This submission is being filed with a Petition for a Five-Month Extension of Time authorizing the U.S. PTO to charge all fees to deposit account 14-1138.

Respectfully submitted,

Date: April 1, 2008

/Edwin V. Merkel/  
Edwin V. Merkel  
Registration No. 40,087

Nixon Peabody LLP  
1100 Clinton Square  
Rochester, New York 14604  
Telephone: (585) 263-1128  
Facsimile: (585) 263-1600